Literature DB >> 11844589

MK-801 induced amnesia for the elevated plus-maze in mice.

Zdenek Hlinák1, Ivan Krejcí.   

Abstract

MK-801, a non-competitive NMDA receptor antagonist, has been shown to have amnesic properties in animal models. The purpose of the present study was to examine potential amnesic effects of MK-801 in mice using the modified elevated plus-maze paradigm. An animal was placed on the distal end of an open arm, and the transfer latency, i.e. the time in which it moves to the enclosed arm, was measured. Four different experimental schedules (i.e. the combination of the treatment and the testing) were used: MK-801 (0.075, 0.15, 0.25 and 0.4 mg/kg or saline) were given (a) 30 min before the acquisition session, (b) immediately after the acquisition session, (c) 60 min after the acquisition session, and (d) 30 min before the retention session. The retention session always followed 24 h after the acquisition session. Analysis of data showed a significant shortening of the transfer latency in saline-treated animals during the retention session. Further, MK-801 (at the dose range of 0.15--0.4 mg/kg) administered before and immediately after the acquisition session as well as before the retention session prolonged the transfer latency during the retention session. In fact, transfer latencies in MK-801 treated mice did not differ from those measured during the acquisition session. Thus, prolongation of the transfer latency in MK-801-treated mice indicates deficits in 'memorization' processes. On the contrary, MK-801 given 60 min after the acquisition session failed to increase the transfer latency, which suggests that the memory trace was sufficiently consolidated at this time. Based on the present results, the glutamatergic NMDA receptor mechanisms play an important role in a spatial orientation of mice placed on the elevated plus-maze.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11844589     DOI: 10.1016/s0166-4328(01)00347-3

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  7 in total

1.  Prenatal corticosteroid exposure alters early developmental seizures and behavior.

Authors:  Libor Velíšek
Journal:  Epilepsy Res       Date:  2011-03-22       Impact factor: 3.045

Review 2.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

3.  Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis.

Authors:  Alexandre S Basso; Dan Frenkel; Francisco J Quintana; Frederico A Costa-Pinto; Sanja Petrovic-Stojkovic; Lindsay Puckett; Alon Monsonego; Amnon Bar-Shir; Yoni Engel; Michael Gozin; Howard L Weiner
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

4.  Oral acetate supplementation attenuates N-methyl D-aspartate receptor hypofunction-induced behavioral phenotypes accompanied by restoration of acetyl-histone homeostasis.

Authors:  Seema Singh; Arnab Choudhury; Priya Gusain; Suhel Parvez; Gautam Palit; Shubha Shukla; Surajit Ganguly
Journal:  Psychopharmacology (Berl)       Date:  2016-01-30       Impact factor: 4.530

5.  The ameliorative effects of sesamol against seizures, cognitive impairment and oxidative stress in the experimental model of epilepsy.

Authors:  Parichehr Hassanzadeh; Elham Arbabi; Fatemeh Rostami
Journal:  Iran J Basic Med Sci       Date:  2014-02       Impact factor: 2.699

6.  7-NI and ODQ Disturbs Memory in the Elevated Plus Maze, Morris Water Maze, and Radial Arm Maze Tests in Mice.

Authors:  Oguz Mutlu; Furuzan Akar; Ipek Komsuoglu Celikyurt; Pelin Tanyeri; Guner Ulak; Faruk Erden
Journal:  Drug Target Insights       Date:  2015-03-04

7.  Zaprinast and rolipram enhances spatial and emotional memory in the elevated plus maze and passive avoidance tests and diminishes exploratory activity in naive mice.

Authors:  Furuzan Akar; Oguz Mutlu; Ipek Komsuoglu Celikyurt; Guner Ulak; Faruk Erden; Emine Bektas; Pelin Tanyeri
Journal:  Med Sci Monit Basic Res       Date:  2014-07-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.